Logo

NCI Launches $14M Breast and Prostate Cancer Initiative; Illumina to Do Genotyping

Feb 13, 2006

NEW YORK, Feb. 13 (GenomeWeb News) - The National Cancer Institute launched an initiative to identify genetic susceptibilities to prostate and breast cancer, the National Institutes of Health announced today.

 

Illumina has been tapped to do rapid genotyping for the project, NIH said, beginning with 2,500 male samples for the prostate cancer portion of the research.

 

The Cancer Genetic Markers of Susceptibility project is a three-year initiative with $14 million in funding, according to a statement.

 

The initiative will analyze as many as 500,000 SNPs in each cancer case or control. NCI's Division of Cancer Epidemiology, Core Genotyping Facility, and Office of Cancer Genomics will coordinate the project.

 

CGEMS data will be available via NCI's caBIG project.

Breaking News
The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.